{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:53:49Z","timestamp":1790855629834,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"MICINN","doi-asserted-by":"publisher","award":["PID2019-110137RB-I00"],"award-info":[{"award-number":["PID2019-110137RB-I00"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"MICINN","doi-asserted-by":"publisher","award":["PLEC2021-008194"],"award-info":[{"award-number":["PLEC2021-008194"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012513","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Cardiovasculares","doi-asserted-by":"publisher","award":["CB16\/11\/00403"],"award-info":[{"award-number":["CB16\/11\/00403"]}],"id":[{"id":"10.13039\/501100012513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2017-SGR-483"],"award-info":[{"award-number":["2017-SGR-483"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2019PROD00122"],"award-info":[{"award-number":["2019PROD00122"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["ICI19\/00039"],"award-info":[{"award-number":["ICI19\/00039"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["ICI20\/00135"],"award-info":[{"award-number":["ICI20\/00135"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/01700"],"award-info":[{"award-number":["PI21\/01700"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/01703"],"award-info":[{"award-number":["PI21\/01703"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PIC18\/00014"],"award-info":[{"award-number":["PIC18\/00014"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD21\/0017\/0022"],"award-info":[{"award-number":["RD21\/0017\/0022"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.biopha.2022.114061","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:59:34Z","timestamp":1670461174000},"page":"114061","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy"],"prefix":"10.1016","volume":"158","author":[{"given":"Gemma","family":"Ferrer-Curriu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Soler-Botija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Charvatova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Motais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Roura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Galvez-Monton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mongui\u00f3-Tortajada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Iborra-Egea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Lup\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Aimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli R.","family":"Bag\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Bay\u00e9s-Gen\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.114061_bib1","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ejhf.312","article-title":"Searching for new mechanisms of myocardial fibrosis with diagnostic and\/or therapeutic potential","volume":"17","author":"Heymans","year":"2015","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.biopha.2022.114061_bib2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00018-013-1349-6","article-title":"The Pathogenesis of Cardiac Fibrosis","volume":"71","author":"Kong","year":"2014","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.biopha.2022.114061_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/cvr\/cvq308","article-title":"Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart","volume":"89","author":"Creemers","year":"2011","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.biopha.2022.114061_bib4","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: Therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2022.114061_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10741-016-9536-9","article-title":"The fibrosis-cell death axis in heart failure","volume":"21","author":"Piek","year":"2016","journal-title":"Heart Fail Rev."},{"key":"10.1016\/j.biopha.2022.114061_bib6","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/CIRCRESAHA.114.302533","article-title":"Myocardial extracellular matrix: An ever-changing and diverse entity","volume":"114","author":"Rienks","year":"2014","journal-title":"Circ. Res"},{"key":"10.1016\/j.biopha.2022.114061_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.115.002613","article-title":"Myocardial fibrosis quantified by extracellular volume is associated with subsequent hospitalization for heart failure, death, or both across the spectrum of ejection fraction and heart failure stage","volume":"4","author":"Schelbert","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.biopha.2022.114061_bib8","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/CIRCULATIONAHA.111.089409","article-title":"Association Between Extracellular Matrix Expansion Quantified by Cardiovascular Magnetic Resonance and Short Term Mortality","volume":"126","author":"Wong","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.114061_bib9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0022-2828(89)90778-5","article-title":"Patterns of Myocardial","volume":"21","author":"Weber","year":"1989","journal-title":"J. Mol. Cell Cardiol."},{"key":"10.1016\/j.biopha.2022.114061_bib10","first-page":"291","article-title":"Factors associated with reactive and reparative fibrosis of the myocardium","volume":"87","author":"Weber","year":"1992","journal-title":"Basic Res Cardiol."},{"key":"10.1016\/j.biopha.2022.114061_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphys.2020.641771","article-title":"Editorial: Cardiac Fibrosis, From Lineage Tracing to Therapeutic Application","volume":"11","author":"Lucia","year":"2021","journal-title":"Front Physiol."},{"key":"10.1016\/j.biopha.2022.114061_bib12","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1161\/CIRCRESAHA.114.302819","article-title":"Dynamic changes in myocardial matrix and relevance to disease: Translational perspectives","volume":"114","author":"Li","year":"2014","journal-title":"Circ. Res"},{"key":"10.1016\/j.biopha.2022.114061_bib13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jacc.2020.06.016","article-title":"Sacubitril\/Valsartan as Antifibrotic Drug: Rejuvenating the Fibrosed HFpEF Heart","volume":"76","author":"Bayes-Genis","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.114061_bib14","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMcibr2201182","article-title":"Fighting Cardiac Fibrosis with CAR T Cells","volume":"386","author":"Friedman","year":"2022","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2022.114061_bib15","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.114061_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science (80-)"},{"key":"10.1016\/j.biopha.2022.114061_bib17","first-page":"21","volume":"32","author":"Sayer","year":"2014"},{"key":"10.1016\/j.biopha.2022.114061_bib18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.36628\/ijhf.2020.0002","article-title":"Angiotensin Receptor-Neprilysin Inhibition ( ARNI) in Heart Failure","volume":"2","author":"Greenberg","year":"2020","journal-title":"Int J. Hear Fail"},{"key":"10.1016\/j.biopha.2022.114061_bib19","first-page":"1388","volume":"102","author":"Brilla","year":"2000"},{"key":"10.1016\/j.biopha.2022.114061_bib20","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jacc.2018.11.042","article-title":"Effects of Sacubitril\/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF","volume":"73","author":"Zile","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.114061_bib21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jacc.2020.05.072","article-title":"Effect of Sacubitril\/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF","volume":"76","author":"Cunningham","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.114061_bib22","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the Randomized Aldactone Evaluation Study (RALES)","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.114061_bib23","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/ejhf.1194","article-title":"Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial","volume":"20","author":"Ravassa","year":"2018","journal-title":"Eur. J. Heart Fail John Wiley Sons Ltd"},{"key":"10.1016\/j.biopha.2022.114061_bib24","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.yjmcc.2010.10.033","article-title":"Transforming Growth Factor (TGF)-\u03b2 signaling in cardiac remodeling Introduction: The biology of TGF-\u03b2","volume":"51","author":"Dobaczewski","year":"2011","journal-title":"J. Mol. Cell Cardiol."},{"key":"10.1016\/j.biopha.2022.114061_bib25","doi-asserted-by":"crossref","first-page":"H512","DOI":"10.1152\/ajpheart.00137.2015","article-title":"Pirfenidone exhibits cardioprotective effects by regulating myocardial fibrosis and vascular permeability in pressure-overloaded hearts","volume":"309","author":"Yamagami","year":"2015","journal-title":"Am. J. Physiol. - Hear Circ. Physiol."},{"key":"10.1016\/j.biopha.2022.114061_bib26","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.hrthm.2010.04.030","article-title":"Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias","volume":"7","author":"Nguyen","year":"2010","journal-title":"Hear Rhythm Elsevier Inc."},{"key":"10.1016\/j.biopha.2022.114061_bib27","first-page":"1477","volume":"27","author":"Lewis","year":"2021"},{"key":"10.1016\/j.biopha.2022.114061_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/hon.2591","article-title":"CAR T-cell therapy: Full speed ahead","volume":"37","author":"Sermer","year":"2019","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.biopha.2022.114061_bib29","first-page":"1","article-title":"New development in CAR-T cell therapy","volume":"10","author":"Wang","year":"2017","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2022.114061_bib30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"June, Sadelain M. Chimeric Antigen Receptor Therapy","volume":"379","author":"Carl","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2022.114061_bib31","first-page":"10","article-title":"Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant","author":"Liu","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2022.114061_bib32","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","article-title":"CD19-targeted CAR T-cell therapeutics for hematologic malignancies: Interpreting clinical outcomes to date","volume":"127","author":"Park","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2022.114061_bib33","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2022.114061_bib34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-CAR T Cells Induce Remissions in CD19-CAR Na\u00efve and Resistant B-ALL","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2022.114061_bib35","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2022.114061_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cti2.1268","article-title":"Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma","volume":"10","author":"Alvarez-Fern\u00e1ndez","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.biopha.2022.114061_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/etm.2020.9440","article-title":"Research advances in chimeric antigen receptor-modified T-cell therapy (Review)","volume":"21","author":"Luo","year":"2021","journal-title":"Exp. Ther. Med"},{"key":"10.1016\/j.biopha.2022.114061_bib38","first-page":"2","volume":"65","author":"Weiskirchen","year":"2019"},{"key":"10.1016\/j.biopha.2022.114061_bib39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1172\/JCI93563","article-title":"Resolution of organ fibrosis","volume":"128","author":"Jun","year":"2018","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2022.114061_bib40","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.trsl.2019.03.001","article-title":"Cardiac fibrosis: Potential Therapeutics Targets","volume":"209","author":"Park","year":"2019","journal-title":"Transl. Res"},{"key":"10.1016\/j.biopha.2022.114061_bib41","series-title":"T Cell Therapy\u2013Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity? JACC CardioOncology","first-page":"97","author":"Ghosh","year":"2020"},{"key":"10.1016\/j.biopha.2022.114061_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy-assesment and managent of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2022.114061_bib43","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-021-01068-0","article-title":"Cardiovascular Toxicities of CAR T-cell Therapy","volume":"23","author":"Patel","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.biopha.2022.114061_bib44","article-title":"Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management","volume":"20","author":"Asnani","year":"2018","journal-title":"Curr. Oncol. Rep. Curr. Oncol. Rep."},{"key":"10.1016\/j.biopha.2022.114061_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.biopha.2022.114061_bib46","doi-asserted-by":"crossref","unstructured":"Linette G.P., Stadtmauer E.A., Maus M.V., Rapoport A.P., Levine B.L., Emery L., Litzky L., Bagg A., Carreno B.M., Cimino P.J., Binder-Scholl G.K., Smethurst D.P., Gerry A.B., Pumphrey N.J., Bennett A.D., Brewer J.E., Dukes J., Harper J., Tayton-Martin H.K., Jakobsen B.K., Hassan N.J., Kalos M., June C.H. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. 2013.","DOI":"10.1182\/blood-2013-03-490565"},{"key":"10.1016\/j.biopha.2022.114061_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: Development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2022.114061_bib48","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.4049\/jimmunol.177.9.5759","article-title":"The First Molecular Basis of the \u201cMissing Self\u201d Hypothesis","volume":"177","author":"Borrego","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2022.114061_bib49","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","article-title":"NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects","volume":"115","author":"Olson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2022.114061_bib50","first-page":"531","volume":"19","author":"Jaiswal","year":"2017"},{"key":"10.1016\/j.biopha.2022.114061_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01179","article-title":"Zotto G Del, Pietra G, Mingari MC, Locatelli F, Moretta L. Killer Ig-like receptors (KIRs): Their role in NK cell modulation and developments leading to their clinical exploitation","volume":"10","author":"Pende","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2022.114061_bib52","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1073\/pnas.95.9.5199","article-title":"HLA-E is a major ligand for the natural killer inhibitory receptor CD94\/NKG2A","volume":"95","author":"Lee","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2022.114061_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00476","article-title":"NKG2D and its ligands: \u2018One for all, all for one\u2019","volume":"9","author":"Zingoni","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2022.114061_bib54","doi-asserted-by":"crossref","first-page":"7641","DOI":"10.1073\/pnas.0502439102","article-title":"The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure","volume":"102","author":"Garrity","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2022.114061_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/cells10050967","article-title":"Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment","volume":"10","author":"Motais","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2022.114061_bib56","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nri3839","article-title":"Perforin and granzymes: Function, dysfunction and human pathology","volume":"15","author":"Voskoboinik","year":"2015","journal-title":"Nat. Rev. Immunol. Nat. Publ. Group"},{"key":"10.1016\/j.biopha.2022.114061_bib57","first-page":"1","article-title":"Fc\u03b3RIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV","volume":"19","author":"Talathi","year":"2019","journal-title":"BMC Infect. Dis. BMC Infect. Dis."},{"key":"10.1016\/j.biopha.2022.114061_bib58","series-title":"An Overview of Monoclonal Antibodies. Semin Oncol Nurs","first-page":"35","author":"Bayer","year":"2019"},{"key":"10.1016\/j.biopha.2022.114061_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines5010007","article-title":"The escape of cancer from T cell-mediated immune surveillance: HLA class I loss and tumor tissue architecture","volume":"5","author":"Garrido","year":"2017","journal-title":"Vaccines"},{"key":"10.1016\/j.biopha.2022.114061_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01124","article-title":"The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy","volume":"8","author":"Paul","year":"2017","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2022.114061_bib61","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-2567.2007.02573.x","article-title":"In vivo kinetics of human natural killer cells: The effects of ageing and acute and chronic viral infection","volume":"121","author":"Zhang","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.biopha.2022.114061_bib62","first-page":"3","article-title":"Are natural killer cells superior CAR drivers?","author":"Klingemann","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.biopha.2022.114061_bib63","first-page":"1157","volume":"19","author":"Hunter","year":"2019"},{"key":"10.1016\/j.biopha.2022.114061_bib64","first-page":"11","article-title":"Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy","author":"Lupo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2022.114061_bib65","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR- Transduced Natural Killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2022.114061_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/v13071365","article-title":"Improved activity against acute myeloid leukemia with chimeric antigen receptor (Car)-nk-92 cells designed to target cd123","volume":"13","author":"Morgan","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2022.114061_bib67","first-page":"1899","article-title":"Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am. J. Cancer Res"},{"key":"10.1016\/j.biopha.2022.114061_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22115899","article-title":"Car-nk cells in the treatment of solid tumors","volume":"22","author":"Wrona","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.114061_bib69","first-page":"1114","volume":"27","author":"Xiao","year":"2019"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222014500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222014500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:26:20Z","timestamp":1779794780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222014500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":69,"alternative-id":["S0753332222014500"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.114061","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.114061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114061"}}